Moderator: Prof Llovet and Prof Iezzi

Learning objectives:

• Review the latest Phase III combination trials updates (TACE + immunotherapy) in HCC
• Understand why vessel reperfusion matters and its clinical relevance for repeatable, super‑selective TACE ​
• Discover BioPearl™ microspheres, the first resorbable drug‑eluting microsphere​
• Review the latest clinical evidence and early real‑world experience with BioPearl™ indifferent treatment intentions and HCC disease stages​
• Explore how BioPearl™ fits into modern TACE strategies focused on liver function preservation and long‑term patient management​

Agenda:

• Welcome and introductions
• TACE in HCC: Navigating current guidelines and latest clinical evidence
• Vessel reperfusion in focus: Scientific rationale and BioPearl™ microspheres’ unique mode of action
• Clinical safety and feasibility findings from the BIOPEARL-ONE
• Optimizing pre-transplant strategy in HCC: The pathological level impact of BioPearl™ microspheres
• Rationale for BioPearl™ TACE to manage large HCC lesions in the absence of SIRT
• Roundtable discussions on the use of BioPearl™ microspheres in HCC
  1. Which Patients? Selection criteria across disease stages
  2. Could BioPearl™ microspheres redefine the role of TACE in combination regimens with immunotherapy?
• Conclusions